SAFETY AND TOLERABILITY OF EXTENDED (96 WEEKS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IN GENOTYPE D PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B

被引：0
|
作者：
Lampertico, Pietro [1 ]
Vigano, Mauro [1 ]
Di Costanzo, Giovan Giuseppe [2 ]
Sagnelli, Evangelista [3 ]
Fasano, Massimo [4 ]
Di Marco, Vito [5 ]
Boninsegna, Sara [6 ]
Farci, Patrizia [7 ]
Fargion, Silvia [8 ]
Giuberti, Tiziana [9 ]
Iannacone, Claudio [10 ]
Massetto, Benedetta [11 ]
Martins, Eduardo B. [12 ]
Colombo, Massimo [1 ]
机构：
[1] Univ Milan, Div Gastroenterol 1, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Milan, Italy
[2] Cardarelli Hosp, Liver Unit, Naples, Italy
[3] SS Anna & Sebastiano Hosp, Infect Dis Unit, Caserta, Italy
[4] Univ Bari, Clin Infect Dis, Bari, Italy
[5] Univ Palermo, Gastroenterol & Hepatol Unit, Di Bi MIS, Palermo, Italy
[6] Univ Padua, Dept Surg & Gastroenterol Sci, Padua, Italy
[7] Univ Cagliari, Dept Med Sci, Monserrato, Italy
[8] Univ Milan, Dept Internal Med, IRCCS Fdn Policlin, Milan, Italy
[9] Azienda Osped Univ Parma, Unit Infect Dis & Hepatol, Parma, Italy
[10] SPARC Consulting, Milan, Italy
[11] Roche, Monza, Italy
[12] Genentech Inc, San Francisco, CA 94080 USA
来源：
HEPATOLOGY | 2010年 / 52卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
135
引用
收藏
页码：387A / 387A
页数：1
相关论文
共 50 条
  • [41] A cost utility analysis of peginterferon alfa-2a (40KD) versus peginterferon alfa-2b (12KD) for the treatment of chronic hepatitis C (CHC) in the UK
    Latimer, NR
    Lewis, GJ
    VALUE IN HEALTH, 2005, 8 (06) : A58 - A58
  • [42] HBeAg-negative chronic hepatitis B: Cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan
    Veenstra, David L.
    Sullivan, Sean D.
    Lai, Ming-Yang
    Lee, Chuan-Mo
    Tsai, Chia-Ming
    Patel, Kavita K.
    VALUE IN HEALTH, 2008, 11 (02) : 131 - 138
  • [43] A RESPONSE GUIDED APPROACH TO PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEKS 12 AND 24 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D CHRONIC HEPATITIS B PATIENTS
    Lampertico, Pietro
    Vigano, Mauro
    Di Costanzo, Giovan Giuseppe
    Sagnelli, Evangelista
    Fasano, Massimo
    Di Marco, Vito
    Boninsegna, Sara
    Farci, Patrizia
    Fargion, Silvia
    Giuberti, Tiziana
    Rothe, Vivien
    Regep, Loredana
    Massetto, Benedetta
    Facchetti, Floriana
    Testa, Angela
    HEPATOLOGY, 2011, 54 : 1021A - 1022A
  • [44] Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients
    Nelson, David R.
    Zeuzem, Stefan
    Andreone, Pietro
    Ferenci, Peter
    Herring, Robert
    Jensen, Donald M.
    Marcellin, Patrick
    Pockros, Paul J.
    Rodriguez-Torres, Maribel
    Rossaro, Lorenzo
    Rustgi, Vinod K.
    Sepe, Thomas
    Sulkowski, Mark
    Thomason, Isaac R.
    Yoshida, Eric M.
    Chan, Anna
    Hill, George
    ANNALS OF HEPATOLOGY, 2012, 11 (01) : 15 - 31
  • [45] Pharmacokinetics of peginterferon ALFA-2A (40KD, PEGASYS) compared to peginterferon ALFA-2B (12KD, pegintron) in naive patients with chronic hepatitis C (CHC)
    Bruno, R
    Sacchi, P
    Ciappina, V
    Maffezzini, E
    Patruno, SFA
    Zocchetti, C
    Filice, G
    JOURNAL OF HEPATOLOGY, 2003, 38 : 129 - 130
  • [46] HBSAG LEVELS DECLINE > 10% DURING 48 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITS B (CHB) FAVORS END OF TREATMENT RESPONSE: PRELIMINARY ANALYSIS OF THE PERSEAS COHORT
    Goulis, Loannis
    Akriviadis, Evangelos
    Karatapanis, Stylianos
    Deutsch, Melanie
    Dalekos, George N.
    Raptopoulou-Gigi, Maria P.
    Drakoulis, Christos
    Mimidis, Konstantinos
    Germanidis, Georgios
    Nikolopoulou, Vasiliki
    Chounta, Athina
    Bakalos, George
    Papatheodoridis, George V.
    HEPATOLOGY, 2011, 54 : 1019A - 1020A
  • [47] Predicting response to peginterferon alfa-2a (40 KD) (PEGASYS®) in Asian patients with HBeAg-positive chronic hepatitis B
    Cooksley, Graham
    Chow, Wan Cheng
    Piratvisuth, Teerha
    Lau, George K. K.
    Mccloud, Philip
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A108 - A108
  • [48] Peginterferon alfa-2a (40KD) (Pegasys®) and ribavirin is an efficacious and safe treatment for chronic hepatitis C in patients with cirrhosis.
    Marcellin, P
    Brillanti, S
    Cheínquer, H
    Cooksley, WGE
    Shiffmann, ML
    Schmidt, WE
    Brunda, M
    HEPATOLOGY, 2002, 36 (04) : 576A - 576A
  • [49] Hepatitis B virus (HBV) genotypes:: Distribution and variation in response to treatment with conventional interferon and peginterferon alfa-2A (40KD) (pegasys®) in HBeAg-positive chronic hepatitis b
    Cooksley, WGE
    Lai, MY
    Piratvisuth, T
    Wang, YJ
    Mahachai, V
    Chao, YC
    Tanwandee, T
    Chutaputti, A
    Chang, WY
    Zahm, F
    Pluck, N
    HEPATOLOGY, 2002, 36 (04) : 636A - 636A
  • [50] Role of baseline and on-treatment quantitative HBeAg in predicting response to peginterferon alfa-2a (40KD) (PEGASYS®) monotherapy in a large, multinational trial of patients with chronic hepatitis B
    Fried, MW
    Liaw, YF
    Luo, KX
    Lau, GK
    Piratvisuth, T
    Cooksley, G
    Marcellin, P
    Thongsawat, S
    Mai, C
    Flisiak, R
    McCloud, P
    Why, D
    Pluck, N
    HEPATOLOGY, 2005, 42 (04) : 268A - 268A
12345